https://www.selleckchem.com/products/U0126.html
The median OS from randomisation was 14.1 months (95% confidence interval [CI] 12.0-17. in the observation arm and 14 months (95% CI 10.9-16.9) in the maintenance arm (p=0.72). The median progression-free survival (PFS) from randomisation was 2.7 months (95% CI 2.6-3.1) in the observation arm versus 5.7 months (95% CI 4.8-7.1) in the maintenance arm (p0.001). Switch maintenance therapy significantly prolonged PFS but not OS and, thus, should not be proposed to elderly patients with advanced NSCLC. Switch maintenance therapy signific
Like
Comment
Share
